This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Heartfailure with preserved ejection function is a lethal form of heartfailure, with few effective treatments. A team has now identified an enzyme, alpha-kinase 2 (ALPK2), that is specifically expressed in the heart and regulates the heartdysfunction that leads to heartfailure with preserved ejection function.
Heartfailure (HF) is a growing worldwide public health issue affecting 64 million people annually 1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.
The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously and functions in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heartfailure. This program is intended to expedite development of novel medical devices. “We
However, researchers said the drug may be helpful in reducing heartfailure risks, including hospitalization, following a heart attack. The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries. About 32% had Type 2 diabetes.
While composite of death and heartfailure hospitalizations was not significantly reduced, empagliflozin may help reduce heartfailure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
Aging is influenced by genetic determinants and comorbidities, among which diabetes increases the risk for heartfailure with preserved ejection fraction. There is no therapy to prevent heartdysfunction in ag.
An increasing number of preclinical and clinical studies have confirmed a causal relationship between heart and brain diseases. Cardiogenic dementia is a cognitive impairment caused by heartdysfunction and has received increasing research attention.
Gorter TM, van Veldhuisen DJ, Bauersachs et al Right heartdysfunction and failure in heartfailure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the HeartFailure Association of the European Society of Cardiology. Eur J Heart Fail.
Heart transplantation remains a vital treatment for end-stage heartfailure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need. Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024.
Patients from higher volume centres more frequently presented in INTERMACS levels 1 and 2, suffered from right heartdysfunction and needed inotropic support. Cumulative follow-up was 10003 patient-years, with a median follow-up of 1.54years (interquartile range 0.523.15). No difference was observed in adjusted 1-year survival.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content